secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0001437749-22-022922
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology licenses alisertib from Takeda; $7M upfront, up to $287.3M in milestones
--------------------------------------------------------------------------------

- Entered exclusive global license for alisertib from Takeda; upfront payment of $7 million.
- Potential regulatory and commercial milestones up to $287.3 million, plus tiered royalties.
- Puma responsible for development, manufacturing, and commercialization globally.
- Must use commercially reasonable efforts in US, UK, France, Germany, Italy, Spain, and Japan.
- Puma can terminate on 120 days' notice; Takeda may terminate if Puma halts activities for >12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922022922/0001437749-22-022922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922022922/pbyi20220922_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-022922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer